Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Regeneron Pharmaceuticals : Sanofi beats profit forecasts, upbeat on prospects for eczema drug

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2017 | 10:30am CEST
A logo is seen in front of the entrance at the headquarters of French drugmaker Sanofi in Paris

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

French drugmaker Sanofi's (>> Sanofi) profit beat forecasts in the first quarter and confirmed its earnings outlook for the year, lifting its shares on Friday.

The results were buoyed by Sanofi's speciality care division Genzyme, as well as vaccines and consumer products it has acquired from Germany's Boehringer Ingelheim.

Earlier this year, Sanofi had warned investors it expected 2017 earnings per share to be stable or slightly lower after its fourth quarter results were affected by an increase in taxes and one-off charges.

The company had also said in 2015 it was not targeting any 'meaningful' profit growth for two years, citing difficulties in its embattled diabetes division.

"Although it has now some margin to deliver actual numbers above guidance, Sanofi also has reasons to wait a bit more before raising it. Diabetes is still a very uncertain market segment to work in," Bryan Garnier analysts said in a note.

However, Sanofi, whose shares were up more than 2 percent at 0805 GMT, said it was confident Dupixent, a drug for moderate-to-severe atopic dermatitis that was approved in the United States at the end of last month, would sell well.

Analysts forecast annual Dupixent sales of more than $4 billion (£3.10 billion) by 2022, according to Thomson Reuters data. Developed with Regeneron (>> Regeneron Pharmaceuticals Inc), the drug is seen as the most important growth driver for the two companies, who have said Dupixent will have a list price of $37,000 a year.

Sanofi Chief Executive Olivier Brandicourt told journalists that he was "very encouraged with the early coverage" of Dupixent, adding that "the launch is delivering so far exactly on our expectations".

While the price of Dupixent before discounts and rebates to insurers is far more expensive than topical medicines and steroids used to treat eczema, it is less expensive than other injectable antibody drugs for serious skin conditions, such as psoriasis, that list for about $50,000 a year.

CONSUMER HEALTHCARE SHINES

Sanofi said on Friday first-quarter business net income rose 1 percent at constant exchange rates to 1.8 billion euros (£1.51 billion). Total sales rose 8.6 percent to 8.65 billion.

Analysts polled by Reuters in partnership with Inquiry Financial had on average been expecting business net profit of 1.6 billion euros and net sales of 8.38 billion.

Genzyme's sales were up 15.5 percent while revenue at the vaccines divisions rose 22.2 percent. Consumer healthcare products sales were up 42.7 percent.

Hurt by continued U.S. pricing pressure, diabetes and cardiovascular sales however suffered another downturn with revenue falling 7.7 percent.

(Additional reporting by Matthieu Protard; Editing by Leigh Thomas and Alexander Smith)

By Matthias Blamont

Stocks treated in this article : Sanofi, Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07/13 REGENERON PHARMACEUTICALS : Reports Outline Immunoglobulins Findings from Regene..
07/13 REGENERON PHARMACEUTICALS : to Report Second Quarter 2017 Financial and Operatin..
07/13 REGENERON PHARMACEUTICALS : Announces the 2017 Winners of the Prize for Creative..
06/29 REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Inc. Repo..
06/29 REGENERON PHARMACEUTICALS : New Epilepsy Study Findings Have Been Reported by Re..
06/29 VEEVA : Standardizing on Veeva Vault Enhances Regeneron's Clinical and Regulator..
06/29 REGENERON PHARMACEUTICALS : Corporate News Blog - Regeneron and Sanofi Announced..
06/27 REGENERON PHARMACEUTICALS : ($REGN) Dips as Biotech Stocks Rebound
06/23 Sonic, Forestar post gains; BlackBerry, Regeneron fall
06/23 MARKETS RIGHT NOW : US stocks open slightly lower
More news
News from SeekingAlpha
06:40a Cypress Semiconductor Will Go To $17 - Cramer's Lightning Round (7/19/17)
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/13 CYTRX : SCLC Study Still Breathing?
07/10 Strong Small Cap Performance Drives Second-Quarter Gains
07/07 NICK'S PICKS 2017 : Halftime Report
Financials ($)
Sales 2017 5 493 M
EBIT 2017 2 187 M
Net income 2017 1 016 M
Finance 2017 2 105 M
Yield 2017 -
P/E ratio 2017 57,52
P/E ratio 2018 45,04
EV / Sales 2017 9,42x
EV / Sales 2018 8,32x
Capitalization 53 867 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 477 $
Spread / Average Target -5,9%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS35.56%53 867
AMGEN22.55%131 769
CELGENE CORPORATION16.63%105 411
GILEAD SCIENCES1.55%95 025
VERTEX PHARMACEUTICALS116.76%39 774
ACTELION20.86%30 319